网络科学能否改变健康与营养领域?

qimuai 发布于 阅读:22 一手编译

网络科学能否改变健康与营养领域?

内容来源:https://www.quantamagazine.org/can-network-science-transform-health-and-nutrition-20261112/

内容总结:

网络科学能否变革健康与营养领域?

网络科学先驱阿尔伯特-拉斯洛·巴拉巴西与主持人史蒂文·斯特罗加茨近日在一档播客节目中展开对话,探讨网络科学的起源、核心思想及其在医学与营养领域的应用前景。巴拉巴西指出,几乎所有事物都存在于网络之中——意识源于神经元的协同活动,生命源于基因与蛋白质的相互作用,社会源于人与人的连接。20世纪90年代,研究者开始绘制从万维网到好莱坞演员合作网络等真实网络,发现这些截然不同的系统共享某些仅靠其组成部分无法解释的结构特征,暗示着网络形成与演化存在共同的组织原则。

巴拉巴西回顾了网络科学的两大推动力:一是互联网带来的数据可获得性革命,使研究者得以绘制细胞代谢网络、社交网络等大规模图谱;二是关键发现——从网络视角审视这些系统时,真实系统在架构上的相似性远多于差异性。这些网络共享的架构特征无法仅用节点和连接的性质来解释,而是指向某种更深层的组织原则。

对话重点讨论了“枢纽”概念。巴拉巴西与斯特罗加茨各自的研究团队在20世纪90年代末发现,万维网的连接分布并不遵循高斯钟形曲线,而是遵循幂律分布——绝大多数网页只有极少数链接,而少数主要枢纽拥有数亿甚至数十亿连接。他们提出,网络通过逐个节点增长并以“优先连接”机制形成,即新节点倾向于连接已高度连接的节点,这自然导致枢纽的涌现。这一机制被称为“无标度网络”,解释了从万维网到好莱坞演员网络、计算机芯片、引文网络等诸多系统的结构。

在医学应用方面,巴拉巴西介绍了“网络医学”的概念。基因组学提供了细胞组分的清单,但未揭示这些组分如何相互作用。许多疾病的根源不在于某个组分本身损坏,而在于突变导致蛋白质变形后无法与其他蛋白质或分子结合,从而破坏网络中的连接。网络医学试图绘制这些相互作用图谱,并利用图谱理解组分损坏后的下游效应及疾病成因,同时寻找干预靶点。研究发现,约85%的药物并不直接作用于疾病相关蛋白,而是作用于下游通路。巴拉巴西团队发现,每种疾病的相关基因并非随机分布,而是聚集在特定的“网络邻域”中,形成“疾病模块”。基于这一思路,他创立的公司开发出通过血液样本预测类风湿关节炎患者对修美乐等药物是否有效的工具,可帮助患者避免每年约9万美元的无效治疗及长达六个月的错误用药期。

对话最后转向营养领域。巴拉巴西指出,基因组仅能解释10%至20%的疾病成因,环境因素——其中饮食是最大因素——解释了其余部分。传统营养学主要关注能量来源、构建 blocks 和维生素等约150种成分,但巴拉巴西团队的Foodome项目数据库目前已收录约13.5万种非营养性分子,他称之为“营养的暗物质”。以多酚为例,这类仅存在于植物中的分子并非为人体提供能量,而是进入细胞后与蛋白质和DNA结合,发挥纯调控作用,如同数千种药物微调细胞活动。这些分子的功能及其对健康的影响才刚刚开始被认识。

展望未来,巴拉巴西认为大脑作为物理网络是重要前沿——神经元通过突触永久连接,其物理性对理解大脑功能至关重要。此外,他希望将网络科学知识应用于材料设计,探索通过3D打印制造具有非常规网络结构的全新材料。斯特罗加茨在总结中指出,网络科学提供了一种宏观视角来理解营养等领域的复杂系统,但它只是起点而非终点,动态系统的 kinetics 与动力学仍有待深入探索。

中文翻译:

网络科学能否改变健康与营养学?

引言

没有任何事物真正孤立存在。我们生活的几乎每一个部分都存在于一个网络之中。意识产生于神经元共同的运作,生命产生于基因和蛋白质共同的运作,社会产生于我们共同的运作。当研究人员在20世纪90年代开始绘制现实世界的网络——从万维网到通过电影相关联的好莱坞演员——他们发现,截然不同的系统共享着某些仅靠其组成部分无法解释的架构特征。这表明,网络的形塑和发展存在着共同的组织原则。

在本期节目中,网络科学的两位先驱——阿尔伯特-拉斯洛·巴拉巴西和联合主持人史蒂文·斯特罗加茨——讨论了这一领域是如何形成的、支撑它的核心思想,以及为什么它不仅仅是换了个名字的图论。随后,对话转向健康和营养学。巴拉巴西解释说,与疾病相关的基因聚集在“网络邻域”中,这可能有助于识别更好的药物靶点,并预测哪些患者会对哪些药物产生反应。这项工作引领他创建了“食物组学”项目,该项目编录了我们所吃食物中的分子,并探究它们在细胞内发挥什么作用。据他统计,约有135,000种化合物存在于传统营养学范畴之外——传统营养学主要关注能量、构建物质和维生素。这些化合物——他称之为“营养学的暗物质”——及其对身体的影响才刚刚开始被理解。

可在Apple Podcasts、Spotify、TuneIn或你最喜欢的播客应用上收听,也可以从Quanta网站流媒体播放。

文字记录

史蒂文·斯特罗加茨:大家好,我是史蒂文·斯特罗加茨。

詹娜·莱文:我是詹娜·莱文。

斯特罗加茨:这里是《为什么的乐趣》。

莱文:一档播客……在这里……你没法逗我笑,好吧。一档来自《量子杂志》的播客,我们在这里探索当今数学和科学中一些最大的未解之谜。

斯特罗加茨:嘿,詹娜,我要带你穿越时空回到20世纪90年代。你想跟我一起去吗?

莱文:当然想。

斯特罗加茨:那时候有一个潮流,人们会玩一个叫“六度分隔”的游戏。

莱文:对,就像凯文·培根游戏。

斯特罗加茨:没错。如果大家不记得了,凯文·培根演过很多电影,围绕他发展出了一个游戏,你随便说一个演员的名字,比如马龙·白兰度或者詹姆斯·迪恩,然后你得找出一条合作演员的路径。你知道,马龙·白兰度跟某个人演过某部电影,那个人又跟凯文·培根演过电影。这样的话,我们就说马龙·白兰度距离两步。他的培根数是二。

莱文:【笑】对。不过这背后有真正的数学基础。我记得你在这方面做了大量工作——我们所有人是如何连接的,世界比我们想象的要小,这是怎么发生的。你知道,你怎么……你认识芝加哥的乔吗?然后你说,“我当然认识乔。”对吧?

斯特罗加茨:嗯,确实如此。我的学生邓肯·瓦茨和我对“六度分隔”的数学非常感兴趣——什么样的网络才能具有这种性质?大约在我们发表论文的时候,不久之后我们就收到了马尔科姆·格拉德威尔的来信——那时他还没有真正作为“马尔科姆·格拉德威尔”出名——他想讨论这个想法,最终写了一篇题为《洛伊丝·韦斯伯格的六度分隔》的文章。

莱文:当然,我认识洛伊丝。

斯特罗加茨:对,这就是重点。每个人都认识洛伊丝。洛伊丝认识芝加哥所有人,还有各地的人。

所以,我们都知道我们的网络中存在着这些“连接者”,而这实际上就是我们在接下来采访拉斯洛·巴拉巴西时某种程度上要听到的内容。

他是东北大学的网络科学家。他还在哈佛医学院和匈牙利布达佩斯的中欧大学有任职。他一直在研究他所谓的“枢纽”的作用。你知道,就是网络中那些像洛伊丝·韦斯伯格一样的超大节点,它们似乎拥有惊人数量的连接,以及它们因此对网络行为产生的影响。

莱文:这可能不仅仅适用于人类社会系统,还适用于其他复杂系统吧?

斯特罗加茨:哦,当然。理解网络——不仅仅从人类社会生活的角度——对我们理解疾病如何在人群中传播,以及大脑如何连接,都产生了各种各样的影响。基因在基因调控网络中如何连接,甚至为我们所有家庭和企业提供能源的发电厂。

所以,是的,其深远影响远远超出了人类社会。为此,让我们请教一位专家。下面有请拉斯洛·巴拉巴西。

【音乐播放】

斯特罗加茨:欢迎来到《为什么的乐趣》,拉斯洛。

阿尔伯特-拉斯洛·巴拉巴西:哦,史蒂夫,这太有意思了。我是播客的忠实听众,《为什么的乐趣》 actually 在我的常听列表上,所以能亲眼看到“酱料是怎么做出来的”真的很有趣。

斯特罗加茨:【笑】嗯,很高兴你能来。为了向听众完全披露,我们认识彼此很久了。到现在肯定快30年了。我想先从回忆往事开始,聊聊网络理论的早期日子。你把职业生涯的大部分时间都用网络的视角来看世界。你为什么不先告诉我们,我们说的网络是什么意思,以及用这种方式看世界给了我们什么?

巴拉巴西:嗯,你忘了披露一个事实——你和我对网络科学领域的创立负有责任,对吧?所以我们曾经也是竞争对手。但让我们谈谈为什么我认为当时我们俩都关心网络。因为从根本上说,没有任何事物是孤立存在的,对吧?一个基因、一个神经元、一个人,孤立地思考它们完全没有意义。它们只有在与其他事物连接时才变得有意义。所以意识实际上是关于神经元共同做了什么。生命是我们的基因和分子共同做了什么。社会是我们共同做了什么。

如果我们倾向于像科学历史上大部分时候那样专注于碎片,我们实际上就错过了“为什么”。为什么我们有智慧?为什么我们有生命?为什么我们有社会?

斯特罗加茨:啊哈。所以这是一种关系性视角。听起来你是在反驳通常那种还原论的稻草人。

巴拉巴西:我们不都是吗?因为,我的意思是,听着。还原论是科学中的关键工具,对吧?没有它,我们做不了网络。我们需要了解碎片。

但我们作为科学家太忙于研究部分,以至于忘记了整体。而网络科学实际上就是这样一门学科,它的起点是你必须绘制出事物如何连接以及为什么这很重要。

斯特罗加茨:你谈到绘制事物的地图,这很有趣,因为在20世纪90年代,特别是90年代后半段,我们每个人和各自的学生都发表了引起巨大反响的论文。那就是你所说的我们开创这个学科的时候。

但你认为在我们起步时,已知了什么,未知了什么?我们集体试图弄明白的是什么?

巴拉巴西:是的。我认为我们中没有人“发现”了网络,对吧?网络已经存在了很长时间,许多学科都意识到了这一点,对吧?在我看来,有两件事发生了变化。

其中之一是数据的可得性,对吧?我们利用互联网带给我们的革命的能力,真正开始把碎片拼在一起,创建细胞中代谢物如何相互连接的图谱,好莱坞演员——你的工作,对吧——如何通过共同电影相互连接的图谱等等。

所以我们所有人都利用的一个真正机会就是数据的可得性。但在我看来,仅凭这一点是不够的,对吧?因为如果数据变得可得,我们仍然可以有生物网络的理论和社会网络的理论,两者不同。

我们和其他人在当时做出的关键发现是,一旦我们从网络视角来看这些系统,真实系统的架构中的相似之处远多于差异。我认为这让我们所有人都感到惊讶,因为我不需要说服任何人,细胞内的代谢网络应该不同于社交网络,或者应该不同于大脑的布线。它们有完全不同的目的、完全不同的尺度、完全不同的被连接的单元,以不同的方式互动。

所以真正让许多物理学家、数学家、生物学家震惊的是,许多这些网络具有共同的架构特征,这些特征不能简单地用节点和连接的性质或组成部分的性质来解释,而是暗示着某种更深层的组织原则在支配着连通性。

斯特罗加茨:说得非常好。很棒。正如你记得的,我也当然记得,这个领域存在地盘之争。你知道,有些人,比如纯数学领域的人会说,“别告诉我网络是新的。我们从18世纪某個时候莱昂哈德·欧拉的哥尼斯堡七桥问题开始就在做图论了。”

那么,比如说,这门学科与更古老的学科——就挑两个吧,图论和社会网络——在哲学和内容上有什么不同?

巴拉巴西:当然。我们非常感谢许多同事——数学界的埃尔德什、雷尼和拉斯洛·洛瓦兹,社会网络界的米尔格拉姆和曼弗雷德·科肯等人——因为他们确实一直在用图论来研究各种与连通性相关的问题。

我认为根本区别在于,一方面,图论学家从未真正费心或有兴趣研究真实网络。而社会网络理论家则局限于非常非常小的网络。一旦其他网络的数据变得可得——从生物网络到非常大规模的社会网络——我们开始看到那些在较小样本中根本无法观察到的特征。

最重要的是——我认为这是关键——我们和所有人都意识到,该领域建立起来的模型,比如从20世纪50年代到90年代末的模型,不足以描述这些系统的现实。所以需要一种非常非常不同的思考方式。

缺失的是,图论和社会网络把图当作制图师来绘制外面有什么,但他们没有太多思考事物是如何形成的。为什么网络是现在这个样子?也就是说,网络不是静态对象。它们是随时间演化的动态实体。我们看到的巨大网络是大规模增长过程的结果,而这种时间演化、这些动力学定义了它们的外观、它们的架构,以及它们做事的能力——也就是活着、思考、作为一个系统运作。

斯特罗加茨:这是一个非常好的观点,存在这种时间维度,而传统图论并不特别关注这一点。你知道,现在我们都只谈论互联网,但对我们90年代的人来说,万维网是一件令人震惊的事情。

这是在社交媒体之前。没有Facebook。这只是互联网上的网页。有一个叫Mozilla的浏览器大约在1994年出现,如果我记得没错的话,你可以开始做我们称之为网上冲浪的事情。所以你开始有这种切身体验——在这个巨大的、神秘的、难以想象的结构中从一个页面跳到另一个页面,而你做了一些开创性的工作,探索在这个直到90年代才存在的奇妙的、怪异的虚拟世界中导航和探索是什么感觉。正如你所说,就像制图学,探索一个全新的世界。

巴拉巴西:我很高兴你提到这一点,因为这为我们打开了网络科学的大门。作为一个历史注脚,我在1995年写了我的第一篇网络论文,但从未发表。它还在预印本档案里。95年和96年,我花时间试图说服计算机科学家帮我绘制万维网,但没有人费心回复。

我发了无数封邮件给当时在构建机器人的人——我们当时不叫搜索引擎,我们叫它们机器人或爬虫——只是请求他们的数据,但没有人费心回复。直到1998年,我的博士后洪正浩(音译)来了,他有非常强的编程能力,我们才终于能够着手那个项目并绘制出来。

让我给听众讲一个历史小轶事,来说明那是个什么样的世界。就在我们绘制了万维网、论文在99年发表之后,我立刻被邀请到旧金山的互联网档案馆做演讲,当时大约有10位演讲者,对吧?

然后有一个人走过来,他在桌子上放了一个大盒子说,“你知道,我刚投资了一家公司,你为什么不拿我的T恤呢?”T恤上印着Google。那是拉里·佩奇作为一名研究生在分发他第一批T恤。

斯特罗加茨:哇。

巴拉巴西:所以,我们和拉里·佩奇所做的根本区别在于,我们只是绘制了网络而不是内容,而他当然关心内容。当然,从长远来看,这个差异值几万亿美元。但尽管如此,这些就是我们如何将互联网、万维网等视为互联系统的根源,正如你所说,它们对我们来说如此自然,以至于我们甚至不再去想它了。

斯特罗加茨:对,当时这是令人震撼的事情。你之前提到了增长这一点,我想回到这个话题——万维网的网络,但无论是生物网络还是从一个小时庄发展起来的城市,网络都不是静态的。它们增长、累积、添加节点、添加连接。你有一个很好的想法——那个非常简单的观察,即网络会增长,可能会在其结构上留下某种印记。所以请告诉我们,你们在万维网的结构上发现了什么,以及其他与这种增长过程有关的网络又有什么发现。

巴拉巴西:哦,我们得稍微极客一下才行,对吧?我是匈牙利人,我在1994年末和95年开始思考网络的原因是,我读了大量匈牙利图论文献——就是那两位数学家保罗·埃尔德什和阿尔弗雷德·雷尼,还有贝拉·博洛巴斯的一本书。

他们有一个非常简单而强大的概念。他们说,“嗯,外面有非常复杂的网络,它们看起来是随机的,那我们为什么不假设它们纯粹是随机的呢?让我们假设节点只是随机连接的。骰子决定谁是的朋友,除了骰子没有别的。”

基于此,他们做了一系列预测,其中一个关键预测是,在一个随机的宇宙中,我们拥有的朋友数量非常相似。极其相似。

所以对我们来说,当涉及到万维网时,最大的震惊是每个节点的链接数不遵循高斯分布——那条俗称的钟形曲线——而是有大量只有极少链接的网页和少数主要枢纽。这纯粹是经验观察。技术上,我们说度分布遵循幂律。这意味着存在主要枢纽将许多小节点连接在一起,这需要一个解释,而增长就在这里起作用。因为我们当时意识到,随机网络的根本局限在于它们假设网络形成的方式是我们有一堆需要以某种方式连接的节点。

但在现实中,网络是通过一次一个节点的增长形成的。节点加入系统。无论是社交网络——人们进来加入俱乐部,还是生物网络——新分子被合成并加入网络,等等。外面存在的每一个网络,无一例外,都是某种长期增长过程的结果。有时是四十亿年,有时是几年,但总是增长。

还有另一个重要的特征——当一个新节点进入系统时,它不是随机选择任何节点,而总是偏向于连接更多的节点。

受欢迎的人更容易被介绍认识。高连接度的蛋白质出于生物学原因更容易实际连接。但从根本上说,新节点倾向于连接到连接更多的节点。这就是我们所说的优先附着。

我们能够证明,这种增长和优先附着是枢纽出现的原因。也就是说,如果一个网络在增长且选择不是随机的,枢纽会自然出现。这是一个如此简单的解释,如此简单地偏离了之前建模中所发生的事情,突然能够解释许多系统,不仅是万维网,还有好莱坞演员网络,还有计算机芯片和引用网络等等。

斯特罗加茨:让我们再谈谈枢纽,因为我认为这是一个微妙的问题。如果一个人之前没有想过这个问题,最初的陈述——有些节点会比其他节点连接得多得多——似乎像是常识,因为我们知道有些朋友非常受欢迎。所以存在差异。存在异质性。每个人都知道这一点。

但你观察到的疯狂之处在于,你可以在互联网上找到不仅多10倍或100倍连接的网站,而是你看到了什么?像百万倍、十亿倍的连接?

巴拉巴西:很多个数量级。万维网上百万和十亿就在那里,对吧?几年前,我记得大多数网页——我的意思是98%的网页——有一到五个链接。但那时Google有八亿个,对吧?所以差异真的是很多个数量级。

差异有多大取决于系统规模。尺寸越大,最小和最大枢纽之间的差异就越大。这也是关键观察。网络越大,枢纽就会变得越大。有一个非常精确的数学定律将网络的规模与枢纽的大小和数量联系起来。

我认为这真正带来了不同。我们不只是说,“嘿,外面有个受欢迎的人。”我们在说,受欢迎的人的数量和大小或受欢迎程度是由网络结构决定的。一旦你理解了网络,你就可以预测这一点。

斯特罗加茨:这个想法后来被称为无标度网络,因为不存在特征尺度。我们应该说,友谊网络在现实生活中并不是真的这样运作的。没有人有一亿个朋友。没有人类能支撑那个。所以我们不是说每个网络都具有这种跨越多个数量级的尺度特性,但很多网络确实有这种特性。

巴拉巴西:绝对如此。而且,让我们谈谈友谊网络。你的亲密朋友是固定的,亲密固定朋友的数量。但当涉及到社交网络和你有多少熟人时,那已经是无标度的了,这已经在许多系统中被证明——从Facebook到Twitter等等。所以如何定义友谊有根本性的区别。如果你把它们定义为熟人、你连接的人,那么那个属性确实成立。

但你完全正确。有一些众所周知的典型网络不是无标度的。外面没有任何物质网络是无标度的,因为比如碳原子有四个电子可以共享。你永远不会把它变成枢纽,对吧?

所以,有很多真实系统——物理学和其他我们关心的系统——不是那种性质的。但许多我们深切关心的系统——从生物网络如蛋白质相互作用和你细胞中的代谢网络,到熟人意义上的社交网络,到一些基础设施网络如互联网——它们遵循那个属性,而这些系统很重要。一旦枢纽存在,它们从根本上改变了系统的行为,这就是为什么我们关心它。

【音乐播放】

莱文:这很有趣,从随机网络模型开始,它在成功方面似乎很辉煌,尽管直觉上感觉它是一种非常糟糕的模拟现实的方式。我的意思是,我不会随机交朋友——你知道,掷骰子——所以我在某种意义上是惊讶的,随机网络模型竟然曾被推崇。

斯特罗加茨:它确实被推崇。我认为为了公正对待它,我们必须记住,在科学和数学中,不同的研究者有不同的目标。取决于你的问题是什么。所以为了公平对待随机模型,埃尔德什和雷尼试图理解的是某种非常非常优美而深刻的东西,但纯粹是数学的。据我所知,他们并没有在思考现实。他们在编一道数学题。我能让你在脑海中想象一下吗——假设桌子上有很多纽扣。我扔下一袋纽扣,然后开始扔一些线,一次一根,随机连接成对的纽扣。这样做了一段时间之后,如果我闭上眼睛拿起一个纽扣从桌上拉起来,什么会跟着一起来?

莱文:一堆其他纽扣。

斯特罗加茨:可能是一堆,对吧?我的意思是,这取决于我们进行到过程的哪个阶段,对吧?如果我做了很长时间,有很多线,当我拿起一个时,我可能拉起一大团。所以埃尔德什和雷尼感兴趣的是当纽扣与线之间存在临界比率时发生的相变。他们表明的是,并不是随着线越来越多你就拉起越来越多的纽扣,而是这是不连续发生的。在某个临界比率,你突然拉起一个巨大的团,而在那个比率以下,你几乎什么都拉不起来。

所以,他们感兴趣的是那个。如何得到一个网络中相变的简单模型?而这个随机连接的网络模型允许他们做数学并证明漂亮的定理。

所以这在数学中经受住了时间的考验,并开创了整个随机图论学科。但几十年来,这是我们拥有的关于巨型网络的唯一模型——除了你们物理学做的那些,你有晶格。你有立方体、最近邻或棋盘图案。你有非常规则的晶格。流行病学中的人有这些随机图。最大的谜团是真实网络是什么样的?它们可能既不是完全随机也不是完全规则的。

莱文:所以这就是枢纽概念的来源吗?在这些真实网络中,当然,我们的朋友真的不是随机掷骰子决定的,而是存在连接枢纽。听到这些真的很有趣,因为它让我想起算法在互联网上实际上是如何运作的——比如提升某人的Twitter账户。一旦开始增长,就真的起飞了,而当算法压制连通性时,整个东西真的被压制了。

斯特罗加茨:这是一个非常好的洞见和类比,因为我们现在生活在一个这种强化效应无处不在的世界里。正如你所说,如果你在互联网上很受欢迎,那么你会被更多地推荐给加入网络的新人,所以富者确实越来越富。我的意思是,这就是它的酷之处的一部分。这种思想预示了现在司空见惯的许多发展。

莱文:对。 fascinating。

斯特罗加茨:好了,自拉斯洛和他的学生做了所有这些工作以来的30多年里,很多事情都变了。所以我们将听到他如何将网络思维应用到一个非常不同的领域——医学、食物和营养学。广告之后继续。

【音乐播放】

斯特罗加茨:欢迎回到《为什么的乐趣》。我们正在与网络科学家拉斯洛·巴拉巴西交谈。

近年来,在90年代末的大繁荣之后,你继续在各个领域做各种开创性的工作,把网络应用到许多不同的领域,比如说医学。网络医学已经成为一个热门领域。

巴拉巴西:确实如此。

斯特罗加茨:那么,对于没听说过网络医学的人,那是什么?

巴拉巴西:嗯,网络医学真正建立在基因组学的肩膀上。基因组学为我们提供了细胞中组成部分的清单。如果你对你的基因组进行测序,你就能精确地得到你有什么基因,因此你体内有什么蛋白质、什么RNA等等。所以这给了我们完整的组成部分清单。但它们没有告诉我们这些部分如何相互作用,谁在与谁互动,谁与谁结合等等。

然而,许多疾病的根源不在于某个组成部分坏了。一个突变做了什么可能导致疾病?通常,它使一个蛋白质变形。蛋白质变形的后果是什么?蛋白质不能与其他蛋白质或其他代谢物连接。要么不能与其他蛋白质结合而不能形成更大的机器,要么不能与另一个分子结合而不能催化化学反应。

所以真正来说,生命的本质或细胞如何运作是通过组成部分彼此之间的连接。细胞中的机器——从线粒体到血红蛋白——是许多蛋白质组装成微小网络并创造出在细胞中做事情的小机器的结果,比如携带氧气。

其余的蛋白质则忙于催化我们谈到的许多化学反应,因为生命的一个特征是,我们体内几乎所有的化学反应都不会自行发生。它们总是需要一个蛋白质催化剂。

那么,什么是网络医学?

网络医学一方面试图绘制这些相互作用的地图,然后利用这些知识——这张地图——来真正理解当一个组成部分坏了会发生什么,下游效应在网络中的哪里,以及最终你因此得到什么疾病。同样重要的是,你如何干预这个网络来治愈那个疾病,修复那个坏掉的组成部分的后果?

斯特罗加茨:因为我之前提到了地盘之争,就像网络科学的情况一样,在我看来,任何有生物医学知识的听众都会想,“网络医学真的是新东西吗?”比如说,细胞生物学的人喜欢谈论的生化通路或信号转导通路,那些只是换了个名字的网络医学,还是它们遗漏了图景的某些部分?

巴拉巴西:他们一直专注于局部效应。所以,一条通路实际上是一组总是一起发生的反应。是的,当然,正如我之前提到的,生物学有150年的历史来系统地绘制每一个反应。但趋势是你成为这个反应及其邻域的专家,而没有方法去审视整个系统,对吧?

为什么这很重要?思考为什么拥有所有这些更大的图景很重要的最简单方式是,我们不知道如何治疗分子缺陷。医学还不知道如何修复一个突变,对吧?有梦想我们会达到那里,但总的来说,我们现有的药物没有一个真正在修复问题的根源。

我们做什么?我们从问题的下游走,我们在下游干预来修复后果。所以,如果一个蛋白质不工作,不催化某个特定的化学反应,那么你开始给病人提供缺失的分子,对吧?所以,为了知道在哪里干预,你需要有谷歌地图。你需要知道事物如何连接,以及你进入的正确点在哪里。

所以我们在——实际上是我回到波士顿、特别是哈佛之后——做的一项研究是,我们研究了外面所有的药物。假设总是认为药物所做的是它与疾病蛋白结合,对吧——在疾病情况下坏掉的蛋白质——用更简单的话说,它修复了问题,对吧?

但在现实中,85%的药物不与任何与疾病相关的东西结合,它们不与我们所说的疾病蛋白或疾病基因结合。它们总是在下游起作用。因为你不想干扰疾病基因。疾病基因通常是参与多个过程的重要基因。你想通过去到基因没有做或蛋白质没有做它该做的事的地方来纠正问题。

所以如果你想发现新药——发现我们所说的药物靶点——我们从基因组筛选中知道了所有的疾病基因,但那还不够。你必须从它们的下游走,而网络医学为你提供了路径,告诉你应该在哪里寻找。

这正是我们在2015年左右在网络医学领域的一个重大发现——每种疾病都有我们所说的疾病模块,这意味着参与疾病的基因不是随机分布在网络中,而是倾向于聚集在某个网络邻域中,对吧?

让我们以纽约市为例,对吧?如果纽约市的地图是细胞的地图,那么你会发现疾病基因不会随机分布在各处。所有精神疾病都在时代广场周围。代谢疾病可能在华尔街周围,也许哮喘在华盛顿广场周围,对吧?

所以在细胞中,存在这些明确定义的网络邻域,疾病就居住在那里。你需要绘制出来,因为那是你需要在那个邻域中扰动来修复问题的地方。

斯特罗加茨:嗯。你给我们的这个地图的视觉形象非常有帮助。但在生物学层面上,我们谈论的实际网络是什么?比如说,是基因调控网络吗?是蛋白质结合网络吗?是蛋白质到疾病的网络?这些事物中的节点和边是什么,只是为了明确一下。

巴拉巴西:当然。绝对。有很多不同的方法来处理它,但在我的实验室,我们专注于我们所说的物理相互作用。

物理相互作用实际上是结合相互作用。所以,你展示的两个例子就是我们关注的。蛋白质-蛋白质结合相互作用,即蛋白质可以成对结合或形成复合物,或者调控相互作用,即蛋白质与DNA结合以启动某个过程或阻断其他过程的情况。

所以,这些是我们构建地图的两种基本物理相互作用。网络医学中的人可以构建其他更虚拟的网络,比如所谓的表达网络。当基因大量表达时,它们一起活跃,然后基于共活性将它们连接起来。

这些也是有效的方法。在我的实验室,我们不太使用它们,因为我们希望始终找到我们所说的作用机制。我们想知道在分子层面上真正发生了什么,为此,你必须有物理相互作用。

真正来说,过去二三十年标志着一项大规模实验努力来绘制这些相互作用。我想说,在过去十年里,这些数据集已经趋同,也就是说我们对这些相互作用有了相当准确的描述。它们不是百分之百完整的,但足够准确,可以真正开始从网络的角度理解疾病。

斯特罗加茨:你有没有一个例子可以给我们——一种疾病或一种药物或一种治疗——其中这种观点,从疾病模块或更大的疾病组学的角度思考,对医学产生了切实的影响?

巴拉巴西:我很高兴你问这个,因为在医学中,事情只有在影响患者时才重要。

但在网络医学的情况下,我们确实有已经上市的产品。其中一个——作为披露——是我创立的一家公司Cypher的产品,我们用网络医学来告诉类风湿关节炎患者什么药物对他们有效。

医学的肮脏秘密是,几乎所有药物只对百分之二十、三十、四十的患者有效。但在类风湿关节炎的情况下,我们设法开发了这样一种工具,可以从血液样本中告诉你,主打药物修美乐是否对你有用。所以这是一个例子,它已经进入市场,患者正在从中受益。

斯特罗加茨:让我们谈谈那个。类风湿关节炎是一种炎症过多的疾病,它困扰你的关节,是这个意思吗?

巴拉巴西:是的,医生称之为自身免疫性疾病,意思是你的免疫系统过度运转,正在攻击你自己的细胞。那个免疫系统和整个过程由一组已知和已被理解的基因控制。我会称之为一个疾病模块。这些是一百到两百个蛋白质,形成一个子网络,那个子网络中的变化通常与类风湿关节炎的出现相关。

正因为这个模块如此之大,当你服用像修美乐这样的药物时,它扰动的是网络的一部分。然而,如果你的缺陷或你的变化在网络的另一部分,它就不会影响你。

网络医学在这幅图景中添加的是,它绘制了它们之间的关系。在这种情况下,我们找到了大约16个基因,它们的活性会系统性地变化,所以这些就是我们所说的生物标志物。它们甚至不需要本身与疾病相关,只是它们携带了疾病的特征。

斯特罗加茨:我明白了。所以那些是警告信号或闪烁的红灯之类的。

巴拉巴西:没错。那些是我们关于那个特定疾病模块健康状态的监测器,那些足以让我们告诉你你是否会对那个特定药物产生反应。

所以,这确实是一个有趣的故事——网络医学绘制疾病所在的邻域,然后用AI构建我们所说的分类器来告诉你药物对你是否有效。

这很重要,因为在修美乐的情况下,这是每年9万美元的治疗费用,而且大约需要六个月或更长时间才能知道药物对你是否有用。

所以,如果我能马上给你一个测试,你一方面不仅节省了9万美元,而且节省了六个月错误治疗的时间,你可以直接去用正确的或更好的药物。

斯特罗加茨:让我看看我是否都理解了。听起来超级有趣。从你描述的方式,我被引导假设类风湿关节炎可能由不同的疾病模块触发,那么自然这种药物不一定能帮助那些患者。

巴拉巴西:疾病模块总是一样的,但你需要扰动模块的不同部分来治疗你。因为想法是,如果这是你的疾病模块,像一个圆,你在圆的左边,你的变化在那里,而修美乐打在右边,修美乐的影响实际上不会一路传到你那里。所以你需要另一种打得更近的药物。

这不仅适用于类风湿关节炎,对吧?对于许多疾病,我们有多种药物,医生在给患者分配一种或另一种药物时做一种猜测游戏或最可能的场景。所以这个特定的网络医学工具集指向一个未来,在那里猜测被去除。

斯特罗加茨:很好。对我来说越来越清楚了,你的地图类比确实有帮助,因为你知道,仅地图本身就——在这些生物未知领域的情况下——省去了很多猜测。

那么,接下来我们能转到食物吗?因为天哪,食物总是上新闻。我们经常用几个相当粗略的类别来思考对我们好或不好的食物:脂肪、糖、碳水化合物、蛋白质、维生素,所有这些。网络思维能帮助我们超越这种对营养中重要事物的粗略看法吗?

巴拉巴西:当然,如果答案是否定的,你就不会问这个问题了。但让我告诉你我们是怎么走到那一步的。这一切都来自网络医学的视角,因为我们在网络医学中使用的所有数据都来自基因组学。然而,基因组学本身无法解释人们得病的程度。

所以例如,当你查看美国人死亡的十大原因,从心脏病到癌症和其他疾病逐一来看,你会发现只有百分之十到二十的疾病因果关系由你的基因组解释。然后你总是问,“其余的在哪里?”对吧?他们说,“嗯,在环境中。”

所以大约五十年前,我们说,“好吧,从细胞视角和网络视角来看,环境意味着什么?环境因素是什么?”当然,我们知道环境因素是什么。有运动、睡眠、压力。但房间里有一个最大的大猩猩,就是食物。饮食,对吧?

所以我们说,“好吧,食物是分子,那我们为什么不以某种方式绘制食物对我们的细胞做了什么?”经典图景是食物所做的是给我们能量,营养学就是处理那个的,对吧?因为最终,营养学处理的是食物中的能量来源——从糖到脂肪到碳水化合物等等。你必须拥有才能生存的一切——通常是能量来源和细胞的一些构建物质,以及维生素——确实被营养学很好地处理了。

所以我们开始绘制食品工业中已知存在于食物中的分子,我们震惊地发现,比营养学告诉我们的要多得多。营养学通常给我们大约150种细胞中的成分,它们被很好地分类了。我们知道在每一种食物中有多少、浓度是多少等等,是否存在。但当我们更深入挖掘时,我们首先意识到有超过20,000种其他分子——不是营养成分——也存在于食物中。

那是大约五六年前。现在我们的数据库有大约135,000种分子,它们不是营养成分,但由我们的食物携带。所以问题是:它们是什么?它们做什么,对吧?这就开始了实验室里的整个食物组学项目。一方面,食物组学专注于绘制已知存在于食物中的分子,第二是它们对我们的细胞做了什么。

斯特罗加茨:哇。这就像人们说我在吃化学物质。当然,一切都是化学物质,包括有营养的那些,但我想他们想到的是所有这些——你说多少?十万种?

巴拉巴西:135,000,我们当前的数据库,对吧?让我们理解它们是什么。让我给你一个例子,我认为能稍微说明这个故事:多酚。

我们知道我们应该多吃水果和蔬菜,因为它们对我们好,对吧?为什么它们对我们好?因为它们有多酚和类黄酮,这些分子你从肉中得不到,或者从其他来源得不到,我们自己也无法生产。所以第一个问题是:为什么肉没有?为什么它们对我们好?我们总是得到答案,它们是抗氧化剂,对细胞好。

但让我们先理清为什么只有植物有?嗯,植物有而动物没有的原因是植物不知道怎么跑。动物差异的很多部分是关于肌肉的。所以我们被优化为使用能量来创造运动。

然而,植物不知道怎么跑,所以它们的防御完全是化学的。为了构建那些化学物质,它们建立了一个庞大的次生代谢。我们有20,000个基因。有些花有150,000个基因,对吧?因为它们需要大量的基因来真正催化我们甚至梦想不到的反应来生产这些东西,对吧? даже洋葱有40,000个基因,是我们的两倍,对吧?所以,要么洋葱超级聪明在做我们不知道的事情,要么,它就是真的在生产洋葱的味道,我们无法生产,但需要庞大的次生代谢来做到。现在,这些多酚对我们好,但它们不是营养成分。它们不给我们提供能量。它们对我们的代谢是不可见的。我们的代谢看不到它们。那么,它们做什么?

嗯,当你吃植物时,它首先被细菌遇到,细菌只是分解东西。但大多数细菌非常渴望糖,所以它们不太费心处理多酚。最终,多酚——其中许多进入你的血液。有些是有毒的。它们在肝脏中被分解一点,然后它们开始在你的细胞中游走。

在那里,它们所做的是开始与你的蛋白质和DNA结合。它们的作用纯粹是调控性的。它们像成千上万的药物一样,微调我们细胞的全套活动。所以它们与我们拥有的所有营养成分有完全不同的作用。

没有它们,从长远来看我们会开始得很多疾病。我们所有人的一个重大挑战是理解多酚和其他135,000种分子对我们做了什么,它们如何调节我们的健康,以及我们如何利用这些知识来进一步改善健康。

斯特罗加茨:嗯。这太奇妙了。我觉得我在准备我们的对话时在某处读到一个与暗物质或暗能量有关的短语。你的短语是什么,暗什么?

巴拉巴西:是的,当我们发表关于第一批20,000种分子的第一篇论文时,我们称之为营养学的暗物质,因为它不存在于营养学的经典之中。我认为很多人只是认为这些是惰性分子,你吃进去又排出来,并不真正影响我们。

但当你更深入地看,有大量散布在文献中的研究表明这个多酚做这个,那个做那个,这个有抗癌作用,那个有其他特性,它们清理细胞中的混乱等等。所以所有这些非营养成分的分子——我刚才说现在大约135,000种——我们称之为营养学的暗物质。

斯特罗加茨:太有趣了。网络科学领域有没有一些重大的开放问题,你可以向我们揭示?你认为现在伟大的前沿是什么?

巴拉巴西:这是个好问题,对吧?当我还是研究生的时候,我遇到了这个领域的一位巨擘,我就像一个眼睛发亮的研究生,我问他,“你是大人物。接下来是什么?”他说,“我不知道,但我可能正在做。”而他并不是。

所以,打个折扣,你知道。通常接下来是什么真正是由下一代给出的,对吧?他们已经在做了,而我们不知道。

但我确实有一些想法。我知道我们的故事中的大洞在哪里,对吧?我们目前正在做的一个正在打开的大机会是大脑。大脑是一个非常特殊的网络。我称之为物理网络,因为连接不再是我們之前谈到的那些握手或人与人之间那种虚拟互动,而是神经元通过突触在我们大脑中永久连接。这种物理性很重要,因为这是一个非常密集的环境,你需要真正理解这些物理网络的性质,才能真正理解为什么大脑看起来是这样,以及最终它如何运作。物理性是那个故事的关键部分,那是我真正兴奋的一个领域。

also 由此而来,在我进入网络之前,我在做材料科学。而且,我看到了一个巨大的机会来重新思考什么样的网络可以成为我们现在看不到的材料,这些材料可以产生与我们现在拥有的任何东西根本不同的材料。我们现有的所有材料要么是规则晶格,要么是随机布线的东西。

我们如何利用我们作为一个社区在过去二三十年积累的丰富知识,对吧?关于复杂网络看起来是什么样的,并把它带回材料空间。这里有一个特别的机会,因为现在我们的3D打印几乎可以到分子尺度。所以那里的问题是,如果你可以3D打印任何你想要的网络,你会打印什么网络?

斯特罗加茨:嗯,谢谢你,拉斯洛。这真的很有趣。我就知道会这样。感谢你来到这里。谢谢。

巴拉巴西:和你一起做这个太有意思了。非常感谢。

【音乐播放】

莱文:那是对暗物质的一种不寻常的使用。让我看看我是否喜欢它。暗物质有什么有趣的?暗物质从技术上讲实际上是不可见的,因为它不相互作用,但在引力上它是深刻而强大的,塑造着宇宙。所以,也许这就是他所说的营养学暗物质的意思。它可能字面上不是营养,但它在塑造健康或我们的反应中扮演着某种其他角色。

斯特罗加茨:我想这就是那个想法,我们摄入的分子,有些是为了建造强壮的骨骼和牙齿,帮助我们制造酶和做各种事情。但有些分子,它们做什么不那么明显。它们不是以同样的方式有营养。正如他所说,它们过去被认为是不活泼的,只是进来又出去,被排泄掉。但现在看起来它们可能具有我们之前没有意识到的功能。真正打动我的是那个数字,超过100,000种这样的分子,它们是“暗”的,因为我们不知道它们是为了什么,而现在我们在想也许它们有抗氧化特性或抗癌特性或whatever。就像有一个新的宇宙等待探索。

莱文:而他们用同样的网络思维在探索它?

斯特罗加茨:就是这个想法,我们要看比如哪些类型的反应通路是连接的——如果同样的多酚出现在两者中,或者类似的东西。你知道,我不知道你是否看过单个细胞中发生了什么事的接线图。所有不同的分子在做所有不同的事情。那是一个令人难以置信的信息纠结。

莱文:对。

斯特罗加茨:所以鉴于人类模式识别能力,有一张地图能帮助我们理解事物。

莱文:是的。有时候只是追踪连通性比跟随一条字面路径要容易得多。我的意思是,我们一直对房间里的空气分子这样做。我们不想做跟随房间里每个分子运动的累人任务。我们实际上想看更大集体的行为,然后我们就有了一个真正有用的量,比如温度,对吧?在我看来,似乎从某种意义上说,通过观察大的集体行为,他们可以在不知道字面路径的情况下弄清楚发生了什么。

斯特罗加茨:是的,我认为这就是精神,这是对营养学中这个巨大的令人困惑的复杂性的更宏观的视角。不是一个平均概念,像温度或压力,它仍然保留网络结构连通性,但另一方面,你说得对,它给了一些过去我们可能只有更近视的理解的东西一个全局视角。

它给了我们在复杂系统更广泛领域的一个起点。当你有一个巨大数量的部分以超级复杂的方式互动时,起点通常是 just 画一个谁与谁互动的图。它们是抑制?是兴奋?就像,最终,作为一个动力系统的人——那才是我心之所系——我想知道的不仅仅是我与你互动。我想知道我的连接的强度。我想知道动力学,那如何运作的动力学。所以,网络科学不是终点。它是起点。

莱文:是的。我们看看这会走向哪里。

斯特罗加茨:嗯,詹娜,谢谢。这是一次非常有趣的讨论,我想我们快到本季的尾声了,对吧?这是我们的最后一集。

莱文:是的,这是我们的最后一集。我会想你的。有太多东西要思考了。

斯特罗加茨:嗯,别做陌生人啊。

莱文:没错。

斯特罗加茨:你知道在哪找到我。

莱文:是的,很高兴见到你,史蒂夫。

斯特罗加茨:是的,很高兴见到你,詹娜。

【音乐播放】

莱文:如果你喜欢《为什么的乐趣》且还没有订阅,在你收听的地方点击订阅或关注按钮。你也可以给节目留个评论。这能帮助人们找到这

英文来源:

Can Network Science Transform Health and Nutrition?
Introduction
Nothing really exists in isolation. Almost every part of our lives exists in a network. Consciousness arises from what neurons do together, life from what genes and proteins do together, society from what we do together. When researchers began mapping real-world networks in the 1990s – from the World Wide Web to Hollywood actors linked by films – they found that wildly different systems shared architectural features that their components alone could not explain. This suggested common organizing principles for how networks form and develop.
In this episode, two of the pioneers of network science – Albert-László Barabási and co-host Steven Strogatz – discuss how the field took shape, the ideas that underpin it, and why this is more than graph theory under a different name. The conversation then turns to health and nutrition. Disease-related genes cluster in “network neighborhoods”, Barabási explains, which may help identify better drug targets and predict which patients will respond to which drugs. That work led him to his Foodome project, which catalogs the molecules found in the food we eat and asks what they do inside our cells. By his count, around 135,000 compounds lie outside conventional nutrition, which concerns itself mainly with energy, building blocks, and vitamins. These compounds, which he calls the “dark matter of nutrition,” and their effects on the body are only beginning to be understood.
Listen on Apple Podcasts, Spotify, TuneIn or your favorite podcasting app, or you can stream it from Quanta.
Transcript
STEVE STROGATZ: Hello, I’m Steve Strogatz.
JANNA LEVIN: And I’m Janna Levin.
STROGATZ: And this is The Joy of Why.
LEVIN: A podcast… where… you can’t make me laugh, okay. A podcast from Quanta Magazine where we explore some of the biggest unanswered questions in math and science today.
STROGATZ: Well, hey, Janna, I’m gonna take you back in a time warp to the 1990s. Do you wanna go there with me?
LEVIN: Yeah, for sure.
STROGATZ: There was a trend back then, where people would play a game that they called Six Degrees of Separation.
LEVIN: Yeah, it was like the Kevin Bacon game.
STROGATZ: Right. So if people don’t remember, Kevin Bacon, he was in a lot of movies and a game developed around him where you would name an actor, whoever, Marlon Brando or James Dean, and then you have to figure out a path of co-stars. You know, Marlon Brando was in such and such movie with somebody who was in a movie with Kevin Bacon. In that case, we would say Marlon Brando was two steps away. He had a Bacon number of two.
LEVIN: [Laughs] Right. Now, this though has some actual mathematical underpinnings. And as I remember, you did substantial work on some of this, how we’re all connected and how the world is smaller than we think, how that happens. You know, how do you… Do you know the guy Joe from Chicago? And you’re like, “Of course I know Joe.” Right?
STROGATZ: Well, it is true. My student Duncan Watts and I got very interested in the math of Six Degrees of Separation, like what would a network have to be like to have that property? And around that time, when we published our paper, soon after we heard from Malcolm Gladwell before he was really famous as Malcolm Gladwell, and he wanted to talk about this idea, and he ended up writing an article that was called Six Degrees of Lois Weisberg.
LEVIN: Sure, I know Lois.
STROGATZ: Yeah, that’s the point. Everybody knows Lois. Lois knew everyone in Chicago and all over the place.
And so, we all know that there are these connectors in our networks, and that’s actually what we’re gonna be hearing about to some extent in this upcoming interview with László Barabási.
So, he is a network scientist at Northeastern University. He’s also got an appointment with Harvard Medical School and with the Central European University in Budapest, Hungary. And he has been looking at the role of what he calls hubs. You know, these outsized Lois Weisberg-like nodes in a network that seem to have a tremendous number of connections and the effect that they have on the behavior of the network as a result.
LEVIN: This probably has application for other complex systems than just human social systems?
STROGATZ: Oh, it certainly does. Understanding networks, not just from the perspective of human social life, has had all kinds of consequences for our understanding of how diseases spread through populations, but also how brains are wired together. The way genes are connected in gene regulation networks, or even the power plants that provide energy to all our homes and businesses.
So, yeah, very big implications way beyond human society. So, for that, let’s turn to one of the experts. Here we go with László Barabási.
[Music plays]
STROGATZ: Welcome to The Joy of Why, László.
ALBERT-LÁSZLÓ BARABÁSI: Oh, Steve, this is so much fun. I am a big listener of podcast, and Joy of Why is actually on my active list, so it’s so much fun to kind of see the sauce being made.
STROGATZ: [Laughs] Well, it’s great to have you here. So just for full disclosure to our listeners, we have known each other a long time. It must be close to 30 years by now. I’d like to begin by going down memory lane with you to the early days of network theory. You spent a lot of your career looking at the world through the lens of networks. Why don’t you start by telling us what we mean by networks, and also what looking at the world this way offers us?
BARABÁSI: Well, you forgot to disclose the fact that we were responsible, you and I, for the field of network science, right? So we were once competitors, too. But let’s talk about why I think both of us cared about the networks at that time. Because fundamentally, nothing exists in isolation, right? A gene, a neuron, a human doesn’t make sense at all to kind of think about them in isolation. They all start making sense when they connect to other things. So consciousness is really about what the neurons do together. Life is what our genes and molecules do together. Society is what we do together.
And if we tend to focus, as much of science did historically, on the pieces, we are actually missing the why. Why do we have intelligence? Why do we have life? Why do we have societies?
STROGATZ: A-ha. So it’s this relational perspective. You’re pushing back against the usual straw man of reductionism, it sounds like.
BARABÁSI: Don’t we all, right? Because, I mean, listen. Reductionism is a key tool in science, right? Without that, we cannot do networks. We need to know the pieces.
But we as scientists got so busy looking at the parts that we have forgotten the whole thing. And then network science is really one of the disciplines whose starting point you gotta map out how things are connected and why that matters.
STROGATZ: It’s interesting you talk about mapping things out, because back in the 1990s, especially towards the second half of the 1990s, each of us with our students wrote papers that made a big splash. That’s what you’re referring to when you speak of us starting the subject.
But what do you think was known at the time we were starting and what was not known? What was it we collectively were trying to figure out?
BARABÁSI: Yeah. So I think none of us discovered networks, right? Networks were there for a long, long time, and many disciplines were aware of that, right? And I think in my mind, two things have changed.
One of them is the availability of data, right? Our ability to take advantage of the revolution that was really brought to us by the internet to really start putting the pieces together and create the maps of how metabolites in the cell are connected to each other, how actors in Hollywood — your work, right — are connected to each other through common movies and so on.
And so one really opportunity that we all took advantage is the availability of the data. But then that by itself, in my mind, would have not been sufficient, right? Because if data becomes available, we could still have a theory of biological networks and a theory of social networks and difference.
The key discovery that we and others had made at that time is once we look from the network perspective of these systems, there are many more similarities in the architecture of real systems than differences. And I think that was surprising to all of us because I don’t have to convince anybody that a metabolic network within the cell should be different from a social network or should be different from the wiring of the brain. They have totally different purpose, totally different scale, totally different units who are being connected in different ways of interactions.
So what really shocked many of us physicists, mathematicians, biologists, is that many of these networks have common architectural features that could not be simply explained by the nature of the nodes and the links or the nature of the components, but it was hinting to some deeper organizing principles that governs connectedness.
STROGATZ: That’s very well expressed. That’s nice. This is a field, as you remember, and I certainly do, there’s a question of turf. You know, there are people, for instance, in pure math, who will say, “Don’t tell me networks are new. We’ve been doing graph theory since the Königsberg bridge problem with Leonhard Euler sometime in the 1700s.”
But so, what are some of the differences in philosophy and content between, say, this subject and the older subjects, let’s just to pick two, graph theory and social networks?
BARABÁSI: Of course. We are very grateful to many of our colleagues, the Erdős and Rényi and the László Lovász of mathematics and the Milgrams and the Manfred Kochens of social networks and so on, because they really been using graph theory to look at various issues related to connectedness.
I think the fundamental difference was that on one end, graph theorists never really bothered or were interested to look at real networks. Social network theorists, however, were limited to very, very small networks. And once the data became available on other networks, from biological to very large social networks, we started features that simply could not be observed at those smaller samples.
And most important — and I think this was the key — we and everybody realized that the models that the field has built up, for instance, the 1950s to pretty much the end of 1990s, were not sufficient to describe the reality of these systems. So there was a need for a very, very different way of thinking about that.
What was missing is that graph theory and social networks were using graphs as kind of cartographers to map out what’s out there, but they were not thinking so much about how things came into being. Why are networks the way they are? That is, networks are not static objects. They are dynamical entities that evolve in time. The large networks we see are the result of massive growth processes and how this temporal evolution, how these dynamics defines the way they look, their architecture, and their ability to do things, which is being alive, to think, to function as a system.
STROGATZ: That’s a really nice point that there is this temporal aspect which was not particularly the concern of traditional graph theory. You know, now we all just talk about the internet, but to us in the ’90s, the World Wide Web was a shocking thing.
This is before social media. There was no Facebook. This was just web pages on the internet. There was a browser called Mozilla that came on around 1994, if I remember right, and you could start to do the thing that we called web surfing. So you started to have this visceral sensation of hopping from page to page through this vast, mysterious, hard-to-picture structure and you did some of the first work pioneering what it was like to navigate and explore this amazing, weird virtual world that didn’t exist until the ’90s. As you say, it’s like cartography, exploring a whole new world.
BARABÁSI: I’m glad you mentioned that because this unlocked network science for us. As a historical note, I wrote my first network paper in 1995 that never got published. It’s still there on the archive. And ’95 and ’96, I spent trying to convince computer scientists to help me map out the World Wide Web, and no one bothered to respond.
I have sent countless emails to people who were building, like, robots at that time. We didn’t call them search engine. We called them robots and crawlers, and just asking for their data, and no one bothered to respond. It wasn’t ’til 1998 when How Hong Jon, my postdoc, who had a very strong programming skill came along, that we could actually finally embark on that project and map it out.
And let me give you a little historical anecdote even for the listeners to indicate what kind of world was that. So right after we mapped the World Wide Web and our paper came out in ’99, I was immediately invited to the Internet Archives in San Francisco to give a talk, and there were about 10 of us speakers there, right?
And there was a guy who came along, and he put a big box on the table and said, “You know, I just funded a company, and why don’t you just take my T-shirt?” And the T-shirt said Google on it. It was Larry Page handing out, as a graduate student, his first T-shirts actually.
STROGATZ: Wow.
BARABÁSI: So, the fundamental difference between what we did and Larry Page did is that we just mapped out the network and not the content, and he, of course, cared about the content. And of course, that difference turned out to be a couple of trillion dollars in the long run. But nevertheless, these were the roots of how do we think about internet, World Wide Web, and so on as interconnected systems that, as you said, they are so natural to us that we don’t any longer even think about that.
STROGATZ: Right, it was a mind-blowing thing at the time. And you made this point earlier that I wanna return to about growth, that the network of the World Wide Web, but also whether it’s biological networks or even a city starting from a small village, networks are not static. They grow, they accrete, they add nodes, they add connections, links. And you had the nice idea that very simple observation, that networks grow, might leave a signature of some kind on their structure. And so tell us about what you found structurally about the World Wide Web, but also about other networks that had some connection to this growth process.
BARABÁSI: Oh, we have to geek out a little bit to do that, right? So I’m Hungarian and why I started thinking about networks back in late 1994 and ’95 is that I read pretty much the Hungarian graph theory literature, which is these two mathematicians, Paul Erdős and Alfred Rényi, as well as there was a book by Béla Bollobás.
And they had a very simple and very powerful concept. They said, “Well, there are very complicated networks out there, and they look random, so why don’t we assume that they’re purely random? Let’s assume that the nodes are just randomly connected.” The dice decide who is your friend and nothing else but the dice.”
And based on that, they made a set of predictions, and one of the key predictions was that in a random universe we are very similar in how many friends we have. Remarkably similar.
So for us, the biggest shock when it came to the World Wide Web, that the number of links per node did not follow a Gaussian, the proverbial bell curve, but rather there were many, many web pages with a very few links and a few major hubs. And that was a purely empirical observation. Technically, we said the degree distribution follows a power law. What it meant is that there were major hubs holding together many small nodes, and that required an explanation, and that’s where growth comes in. Because what we realized back then is that the fundamental limitation of the random networks is that they assume that the way networks form is that we have a bunch of nodes that need to be somehow connected.
But in reality, networks form by one node at a time growing. Nodes join the system. Whether it’s a social network and people come in and join the club, whether it’s a biological networks where new molecules are being synthesized and joining the network, and so on. Every network that is out there, without exception, is the result of some kind of long-lasting growth process. Sometimes four billion years, sometimes a few years, but it’s always growth.
And there was another feature what was also important is that when a new node comes in the system, it doesn’t just randomly pick any node, but it’s always biased towards the more connected nodes.
Popular people are easier to be introduced to. Highly connected proteins are easier to actually connect to for biological reasons. But fundamentally, new nodes tend to connect to the more connected nodes. This is what we call preferential attachment.
And this growth and preferential attachment, we were able to show is responsible for the emergence of the hubs. That is, if a network is growing and the choices are not random, hubs will naturally emerge. And this was such a simple explanation, such a simple deviation from what has happened in modeling that existed before, and suddenly was able to explain lots of systems, not only the World Wide Web, but even the Hollywood actor network but also like computer chips and citations and so on.
STROGATZ: Let’s talk a little more about the hubs, because I think this is a tricky point. If a person hasn’t thought about it before, the initial statement that some nodes are gonna be much more connected than others sort of seems like common sense in that we know some of our friends are very popular. So there are differences. There is heterogeneity. Everybody knows that.
But the crazy thing you observed is that you could find sites on the internet that didn’t just have 10 times more or 100 times more, but you saw things with what? Like a million, a billion times more connections?
BARABÁSI: Many orders of magnitude. And that the millions and billions is there for the World Wide Web, right? A few years ago, I remember that most web pages, what I mean 98% of the web pages have one to five links. But then Google had eight hundred million at that time, right? So the difference is really many orders of magnitude.
And how much is the difference depends on the system size. The bigger the size, the bigger is the difference between the small and the biggest hub. And this was also key observation. The bigger the network, the bigger the hubs will become. And there’s a very precise mathematical law that connects the size of the network to the size and the number of the hubs.
And I think this was really what made a difference. We’re not just saying, “Hey, there’s a popular guy out there.” We were saying the number and the size or the popularity of the popular guys is fixed by the structure of the network. And once you understand the network, you can predict that.
STROGATZ: That idea, it came to be called scale-free networks, because there was no characteristic scale. We should say friendship networks don’t really work like this in real life. Nobody has 100 million friends. No human can support that. So we’re not saying here that every network has this property of scale spanning many orders of magnitude, but lots of networks did have that property.
BARABÁSI: Absolutely. And, let’s talk about friendship networks. Your intimate friends is fixed, the number of intimate fixed friends. But when it comes to social networks and how many acquaintances you have, that is already scale-free, and that has been shown in many systems from the Facebook to the Twitter and so on. So there’s a fundamental difference of how you define friendship. If you define them as acquaintances, people you connect to, then that actually properties holds.
But you’re absolutely right. There are well-known canonical networks that are not scale-free. None of the material networks that are out there are scale-free because like a carbon atom has four electrons to share. You will never turn it into a hub, right?
So, there are lots of real systems that physics and other systems we care about that are not of that character. But many systems that we deeply care about, from biological networks like protein interactions and metabolic networks in your cell to social networks in the sense of acquaintance networks, to some infrastructure networks like the Internet, they follow that property and these systems matter. And once hubs are there, they fundamentally change their behavior, and that’s why we care about that.
[Music plays]
LEVIN: This is interesting, just starting with the random network model, which seems to have been brilliant in its successes, despite the fact that intuitively it feels like a very poor way of emulating reality. I mean, I don’t make friends at random, you know, toss of the die, and so I was surprised in some sense that the random network model was ever sort of revered.
STROGATZ: It is revered. And I think to do justice to it, we have to remember that in science and math, different researchers have different goals. Depends what your question is. So to give a fair shake to the random model, what Erdős and Rényi were trying to understand was something really, really gorgeous and deep, but pure mathematical. They weren’t thinking about reality as far I can tell. They were making up a math problem. Can I ha- just have you picture in your mind, suppose I had a lot of buttons on the table. I just throw down a bag of buttons, and now I start throwing down some threads, one at a time and connect pairs of buttons at random. After I’ve done that for a while, if I close my eyes and pick up a button and pull it off the table, what will come with it?
LEVIN: A bunch of other buttons.
STROGATZ: It might be a bunch, right? I mean, it depends how far into the process we are, right? If I’ve done this for a long time and there’s a lot of threads, when I pick up one, I might pick up a big clump along with it. And so what Erdős and Rényi were interested in was the phase transition that occurs when there’s a critical ratio of buttons to threads. And what they showed was that it’s not that you pick up more and more buttons as a function of more and more threads, it’s that this happens discontinuously. At a certain critical ratio, you suddenly pick up a gigantic clump, and below that ratio, you pick up almost nothing.
So, they were interested in that. How do you get a simple model of a phase transition in a network? And this network model with random connections allowed them to do the math and prove beautiful theorems.
So that has stood the test of time in math, and it opened up a whole subject of random graph theory. But for decades, that was the only model we had of giant networks other than what you guys in physics do where you have crystal lattices. You have cubic, you know, nearest neighbor or checkerboard patterns. You have very regular lattices. People in epidemiology have these random graphs. The big mystery was what are real networks like? They’re probably not perfectly random or perfectly regular.
LEVIN: So is this where the idea of hubs comes in? In these real networks, of course, our friends really aren’t laid down by a random toss of the die, but instead there are hubs of connectivity. And, and it really is interesting hearing some of this ’cause it reminds me of how algorithms really work on the internet in terms of boosting someone’s Twitter account, for instance. And once that starts to grow, it really takes off, whereas when the algorithm suppresses the connectivity, the whole thing is really suppressed.
STROGATZ: That’s a really nice insight and an analogy because we’re now living in a world where these kinds of reinforcement effects are everywhere. As you say, like, if you’re popular on the internet, then you get recommended more to new people joining the network, and so the rich do get richer. I mean, that’s part of what’s cool about this. This kind of foreshadowed a lot of developments that are now commonplace.
LEVIN: Right. Fascinating.
STROGATZ: Alright, well, a lot has changed in the 30-plus years since all of this work of Laszlo and his students. So we’re gonna be hearing how he has been applying network thinking to a really different space — medicine, and food, and nutrition. More on that after the break.
[Music plays]
STROGATZ: Welcome back to The Joy of Why. We’re speaking with network scientist, László Barabási.
You’ve, in more recent years, after this big boom in the late ‘90s, continued to do all kinds of pioneering work in applying networks to many different domains, let’s say medicine. Network medicine has become a thing.
BARABÁSI: It is a thing.
STROGATZ: So, for people who haven’t heard of network medicine, what is that thing?
BARABÁSI: Well, network medicine really built on the back of genomics. Genomics provide us the list of the components in the cell. If you sequence your genome, you get precisely what genes you have, hence what proteins you have, what RNA you have in your body, and so on. So that gave us a complete inventory of the components. But they didn’t tell us how the pieces interact, who is interacting, who is binding to whom, and so on.
However, many diseases are rooted not in the fact that a component is broken. What does a mutation do that may cause a disease? Typically, it deforms a protein. What’s the consequence of deforming the protein? That the protein cannot link to other proteins or other metabolites. Either cannot bind to other proteins and cannot form bigger machineries, or cannot bind to another molecule and cannot catalyze a chemical reaction.
So really, the essence of life or how the cell works is through the connections that the components have to each other. The machineries in the cell, from mitochondria to hemoglobin, are the result of many proteins assembling tiny networks and creating little machineries that do things in the cell, like carry oxygen.
And the rest of the proteins are busy catalyzing the many chemical reactions that we talked about it, because one of the features of life is that virtually none of the chemical reactions that we have in our body take place by themselves. They always need a protein catalyzer for that.
So, what is network medicine?
Network medicine, on one end, tries to map out these interactions and then use that knowledge — the map — to really kind of understand what happens when a component is broken and downstream, where the effects are within the network, and eventually what disease you get as a result. And equally important is like how do you intervene into this network to cure that disease, to fix the consequences of that broken component?
STROGATZ: Since I mentioned turf wars earlier, like in the case of network science, it would seem to me that any biomedically savvy person listening to this would think, “Is network medicine really something new?” Say, a biochemical pathway or a signal transduction pathway that the people working in cell biology like to talk about, are those just network medicine by another name, or, or were they missing some part of the picture?
BARABÁSI: They were always focused on the local effects. So, a pathway is really a set of reactions that always occur together. And yes, of course, as I mentioned earlier, there was a 150-year history in biology to systematically map each of these reactions out. But the tendency was that you became an expert on this reaction and the neighborhood, and there was no way to interrogate the full system, right?
And why does that matter? The simplest way to think about why it matters to have all of this bigger picture is because we don’t know how to treat molecular defects. Medicine does not yet know how to fix a mutation, right? There are dreams that we will get there, but by and large, none of the drugs that we have out there is really fixing the cause of the problem.
What do we do? We go downstream from the problem, and we intervene down there to fix the consequences. So, if a protein is not working and is not catalyzing a particular chemical reaction, then you start giving them the molecule that is missing to the patient, right? So, for you to know where to intervene, you need to have the Google Map. You need to know how things are connected and what’s the right point where you enter.
So one study we did actually once I returned to Boston, to Harvard in particular, was that we looked at all the drugs out there. And the hypothesis always is that what a drug does is that it binds to a disease protein, right, a protein that is broken in the case of the disease. And shorter of a better term, it fixes the problem, right?
But in reality, 85% of the drugs do not bind to anything related to the disease, that they don’t bind to what we call disease proteins or disease genes. They always act downstream. Because you don’t wanna mess with the disease genes. The disease genes are often very important genes that are involved in multiple processes. You wanna kind of correct the problem by going where the effect is that the gene is not doing or the protein is not doing what it’s doing.
So if you wanna discover new drugs — discover what we call drug targets — we know all the disease genes from genomic screening, but that’s not enough. You have to go downstream from them, and network medicine gives you the pathways to say where should you look.
And this is exactly one of our big discovery, back around 2015, in the network medicine space, that every disease has what we call a disease module, which means that the genes involved in the disease are not randomly distributed in the network, but they tend to agglomerate in a certain network neighborhood, right?
Let’s take New York City, right? If the map of New York City would be the map of a cell, then you would find that you know the disease genes would not be randomly distributed around it. But all mental diseases are all around Times Square. And metabolic diseases may be around Wall Street, and maybe asthma would be all around Washington Square, right?
So in the cell, there are these well-defined network neighborhoods where the disease resides. You need to map that out because that’s where you need to perturb in that neighborhood to fix the problem.
STROGATZ: Hmm. It’s very helpful, this visual you’re giving us of maps. But what is the actual network that we’re talking about at the biological level? Is it, say, a gene regulation network? Is it a protein binding network? Is it a protein-to-disease network? What are the nodes and what are the edges in some of these things just to make them explicit.
BARABÁSI: Sure. Absolutely. There are many different ways to approach it, but in my lab, we focus on what we call physical interactions.
Physical interactions are really binding interactions. So, the two examples you showed are those that we focus on. Protein-protein binding interactions, which are the proteins that can bind either pairwise or form complexes, or regulatory interactions, which is the situation when the protein binds to the DNA to initiate some process or block some other processes.
And so, these are kind of the two fundamental physical interactions from which we build our maps. People in network medicine can build other networks that are more virtual, like so-called expression networks. When genes are very much expressed, they’re active together, then they connect them based by co-activity.
Those are also valid ways of doing that. We, in my lab, don’t use them so much because we would like to find always what we call the mechanism of action. We wanna know what really happens at the molecular level, and for that, you must have the physical interactions.
And really, the last kind of twenty, thirty years was marked by a massive experimental effort to map these interactions out. And I would say that in the last ten years, these datasets have converged, which is to say we have a rather accurate description of what are these interactions. They are not a hundred percent complete, but they’re accurate enough to really start understanding disease from the perspective of a network.
STROGATZ: Do you have an example you could give us of a disease or a drug or a treatment where this point of view, thinking in terms of disease modules or the larger diseaseome, had a tangible impact on medicine?
BARABÁSI: I’m glad you asked that because in medicine, things only matter if they impact the patient.
But in case of network medicine, we do have products that are out there. One of them, as a matter of disclosure, is a product of a company that I founded, Cypher, where we used the network medicine to tell patients with rheumatoid arthritis, or RA, what drugs works for them.
The dirty secret of medicine is that virtually most drugs are only effective to twenty, thirty, forty percent of the patients. But in the case of RA, we managed to develop such a tool that from a blood sample, can tell you whether the leading drug, Humira, will work for you or not. So that’s one example where this is already has hit the market and patients are benefiting from it.
STROGATZ: Let’s talk about that. So rheumatoid arthritis is a disease where you have too much inflammation, and it’s bothering your joints, is that the idea?
BARABÁSI: Yeah, so, medical doctors call it an autoimmune disease, which means that your immune system is into overdrive and is attacking your own cells. And, that immune system and the whole process is governed by a set of genes who are known and understood. I would call a disease module. These are a hundred to two hundred proteins who form a sub-network, and the kind of changes in that sub-network are typically associated with the emergence of RA.
And precisely because this module is so large, when you take a drug like Humira, that is perturbing one part of the network. However, if your defect or your changes are in a different part of the network, it will not impact you.
And what network medicine adds to this picture is that it maps out the relationships between them. In this case, we find about sixteen genes whose activity systematically changes, and so these are what we call biomarkers. They don’t even need to be themselves associated with the disease, except they carry the signature of the disease.
STROGATZ: I see. So those are the warning signals or the flashing red lights or something.
BARABÁSI: That’s right. Those are our monitors about the state of the health of that particular disease module, and those are sufficient for us to tell you whether you will respond or not to that particular drug.
So, it’s really was an interesting story of a combination of network medicine mapping out the neighborhood where the disease resides, and then using AI to build what we call a classifier to tell you whether for you or will the drug will work or not.
And this matters because in the case of Humira, this is a $90,000 treatment per year, and it takes about six months or longer to know whether the drug has an effect for you, whether it works for you or not.
So, if I can give you a test right away, you are on one end, not only saving $90,000, but you are saving six months of wrong treatment that you can go right away to the right one or the better one.
STROGATZ: Let me see if I got all that. It sounds super interesting. I’m led to assume from the way you’re describing it that rheumatoid arthritis could be triggered by a different disease module, and then naturally this drug would not necessarily help those patients.
BARABÁSI: A disease module is always the same, but you would have to perturb a different part of the module to treat you. Because the idea is that if this is your disease module, like a circle, and you’re on the left-hand side of the circle where your changes are, and Humira is hitting on the right-hand side, the impact of Humira will not actually travel all the way to you. So you need another drug that hits closer to you.
And this is not only for RA, right? For many diseases, we have multiple drugs, and doctors do a kind of a guess, guessing game or most likely scenario when they assign one drug or the other to the patient. And so this particular network medicine toolset points to a future where that guesswork is taken out.
STROGATZ: It’s nice. It’s becoming clear to me, and your map analogy really does help because, you know, just the map itself in the case of these biological unknown territories is- saves a lot of guesswork.
So, can we move over to food next? Because man, food is in the news all the time. We often think about food that’s good for us or bad for us in terms of a few pretty coarse categories: fat, sugar, carbohydrates, protein, vitamins, all that. Can network thinking help us go beyond that kind of coarse view of what’s important in nutrition?
BARABÁSI: Of course, you wouldn’t ask the question if the answer would not be yes. But let me tell you how we got to that. It all came from the network medicine perspective because all the data that we use in network medicine comes from genomics. However, genomics alone cannot explain the degree that people get a disease.
So for example, when you look at the top ten reasons why people die in the United States, and you take them one by one from heart disease to cancers and other things, you find that only ten to twenty percent of the disease causation is explained by your genome. And then you always ask, “Where’s the rest?” Right? And they say, “Well, it’s in the environment.”
So about fifty years ago, we said, “Okay, well, what does this mean from a cellular perspective and a network perspective, that environment? And what are the environmental factors?” And of course, we know what the environmental factors are. There are exercise, there are sleep, there are stress. But there’s one gorilla in the room that is the biggest, which is food. Diet, right?
And so we said, “Okay, food is molecules, so why don’t we just map out somehow what does food do to our cells?” And the canonical picture is what food does is gives us energy, and nutrition is dealing with that, right? Because at the end, nutrition deals with the energy sources in the food from sugars to fats to carbohydrates and so on. And everything that you must have to survive, which is typically energy sources and some of the building blocks of the cells, as well as vitamins, are really well treated by nutrition.
So we started to map out what are the molecules that are known in the food industry to be in the food, and we were shocked to realize that there are many more than what nutrition tells us. Nutrition typically gives us about 150 components that are in the cell, and they are very well categorized. We know in every single food how much of that, what is the concentration and so on, whether it’s there or not. But then as we dig deeper, we realized first that there were more than 20,000 other molecules that are not nutritional components that were also in the food.
That was about five, six years ago. Now our databases have about 135,000 molecules that are not nutritional components that are carried by our food. So the question is: What are they? What do they do, right? And that kind of started the whole Foodome Project in the lab. On one end, the Foodome is focusing on mapping out what are the molecules that are known to be in the food, and the second one is that what do they do to our cells?
STROGATZ: Wow. This is like when people say I’m eating chemicals. Of course, everything’s a chemical, including the nutritious ones, but I think what they have in mind is all these — what did you say? A hundred thousand of them?
BARABÁSI: 135,000, our current database, right? And let’s understand what they are. So let me give you one example that I think illuminates a little bit the story: polyphenols.
We know that we’re supposed to eat lots of fruits and vegetables because they’re good for us, right? Why are they good for us? Because they have polyphenols and flavonoids, which are molecules that you don’t get in meat, or you don’t get in other sources, nor can we ourselves produce it. So, the first question is: why doesn’t meat have it? And why are they good for us? Always we get the answer, they’re antioxidant, they’re good for the cell.
But so, let’s first clean up why only plants have it? Well, the reason plants have it and animals don’t is because the plants don’t know how to run. Much of the animal difference is about muscles. So, we are optimized to create really, to use energy to create movement.
However, plants don’t know how to run, so their defense is totally chemicals. And to build those chemicals, they built a massive secondary metabolism. We have 20,000 genes. There are some flowers that have 150,000 genes, right? Because they need that massive amount of genes to really catalyze reactions that we don’t even dream about to produce these things, right? Even onion has 40,000 genes, twice as we do, right? So, either the onion is super intelligent doing things that we don’t know, or right, it’s just really producing that taste of the onion, which we cannot produce, but requires a massive secondary metabolism to do. So now, these polyphenols are good for us, but they are not nutritional components. They don’t provide energy to us. They’re invisible to our metabolism. Our metabolism does not see them. So, what do they do?
Well, when you eat a plant, it first is being encountered by the bacteria, which just break up things. But mostly bacteria are really eager to get sugar, so they don’t bother too much with the polyphenols. Ultimately, polyphenols, many of them get into your blood. Some of them are toxic. They’re being broken up a little bit in your liver, and then they will start going around in your cells.
And there, what they do is they start binding to your proteins and DNA. Their role is purely regulatory. They act like thousands of drugs that are micro-modulating the full activity of our cells. So they have a totally different role than all the nutritional components that we have.
Without them, we will start having lots of diseases in the long run. And one of the big challenge for all of us is to understand what polyphenols and the other 135,000 molecules do to us, how they modulate our health, and how could we use that knowledge to further improve health?
STROGATZ: Hmm. This is marvelous. I feel like I read somewhere while preparing for our conversation a phrase connected to something like dark matter or dark energy. What is your phrase, dark what?
BARABÁSI: Yeah, so when we published the first paper about the first 20,000 molecules, we called it the dark matter of nutrition because it’s not existing between the canon of nutrition. And I think many people simply thought that these are just inert molecules that you go in and goes out and doesn’t really affect us.
But when you look deeper, there’s lots of spread around literature about showing this polyphenol does this, that does that, this has anti-cancer, that has other properties, they clean up the cell from mess and so on. And so all these molecules that are non-nutritional components, which I said right now we’re about 135,000, we call it the dark matter of nutrition.
STROGATZ: So interesting. Are there some big open questions in this field of network science that, that you could reveal to us? What do you think are the great frontiers now?
BARABÁSI: It’s a good question, right? When I was a graduate student, I met one of the luminaries of the field, and I was like a bright-eyed graduate student, and I ask him, “You’re the big guy. What’s next?” and he said, “I don’t know, but I’m probably working on it.” And he was not.
So, grain of salt, you know. Often what’s next is really given by the next generation, right? They’re already working on it, and we don’t know that.
But I do have some ideas. I know where the big holes are in our story, right? One of them that we’re currently working on is a big opportunity opening up is the brain. Brain is a very special network. I call it a physical network because the links are no longer these handshakes that we talked about earlier or these kind of virtual interactions between the people, but the neurons are permanently connected by synapses in our brain. And that physicality matters because it’s a very dense environment, and you need to really understand the properties of these physical networks to really understand why the brain looks the way it does and ultimately how it functions. Physicality is a key part of that story, and that’s one area that I’m really excited about.
Also coming from that, before I came to networks, I was doing material science. And, I see a great opportunity to rethink what kind of networks could be materials that we don’t see now that could give rise to materials that are fundamentally different from anything that we have today. All the materials we have out there are either regular lattices, or randomly wired things.
How could we use this wealth of knowledge that we as a community have accumulated in the last 20-wise, 30 years, right? About how many complex networks look like and bring it back to the material space. And there’s a particular opportunity here because now we have 3D printing almost down to the molecular scale. So the question there is, if you could 3D print any networks you want, what network would you print?
STROGATZ: Well, Thank you, Laszlo. This was really fun. I knew it would be. Appreciate having you here. Thank you.
BARABÁSI: So much fun to do this with you. Thank you so much.
[Music plays]
LEVIN: That’s an unusual use of dark matter. Let me see if I like it. What is it about dark matter that’s interesting? So dark matter technically is invisible actually because it’s non-interacting, but gravitationally it’s profound and strong and sculpts the universe. So, maybe that’s the sense in which he means there’s a dark matter of nutrition. It might not literally be nutrition, but it’s playing some other role in sculpting health or our reaction.
STROGATZ: I think that’s the idea, that the molecules that we take in, some of them are for building strong bones and teeth, and help us make enzymes and do all sorts of things. But some of the molecules, it’s not so obvious what they’re doing. They’re not nutritious in the same way. And as he says, they used to be thought to be inert, just come in and go out, get excreted. But now it’s looking like they may have functions that we didn’t appreciate before. What really hit me was that number, over 100,000 such molecules that are dark in the sense that we didn’t know what they were for, and now we’re thinking maybe they have antioxidant properties or anti-cancer properties or whatever. It’s like there’s a new universe to explore.
LEVIN: And they’re exploring it using the same kind of network thinking?
STROGATZ: That’s the idea, that we’re gonna look at like which type of reaction pathways are connected if this same polyphenol occurs in both of them, or something like that. You know, I don’t know if you’ve ever looked at a wiring diagram of what goes on in a single cell. All the different molecules that are doing all these different things. It’s an incredible snarl of information.
LEVIN: Right.
STROGATZ: And so given human ability at pattern recognition, it helps us to make sense of things to have a map.
LEVIN: Yeah. Sometimes it’s much easier just to track connectivity than it would to follow a literal path. I mean, we do that with the air molecules in a room all the time. We don’t wanna do the exhausting task of following the motion of every molecule in the room. We actually wanna look at the behavior of the larger collective, and then we have a really useful quantity like temperature, right? It sounds to me like there’s a sense in which by looking at the large collective behavior, they can kind of figure out what’s going on without knowing the literal path.
STROGATZ: Yeah, I think that’s the spirit, that this is a more macroscopic view of this enormous bewildering complexity in nutrition. Rather than an average concept, like a temperature or a pressure, it still retains network structure connectivity, but on the other hand, you’re right that it’s giving a global perspective to something that in the past we might have only had a more myopic understanding of.
And it gives us a place to start in the broader area of complex systems. When you have a gigantic number of parts interacting in super complicated ways, the starting point is often to just make a diagram of who’s interacting with who. Are they inhibiting? Are they exciting? Like, ultimately, as a person in dynamical systems, which is really where my heart is, I wanna know more than just I interact with you. I wanna know the strength of my connection. I wanna know the kinetics, the dynamics of how that works. So, network science is not the end. It’s the beginning.
LEVIN: Yeah. We’ll see where this goes.
STROGATZ: Well, Janna, thanks. This has been a really interesting discussion, and I guess we’re coming to the end of our season, aren’t we? This is our last episode.
LEVIN: Yeah, this is our last episode. I’ll miss you. There’s so much to think about.
STROGATZ: Well, Don’t be a stranger, man.
LEVIN: Exactly.
STROGATZ: You know where to find me.
LEVIN: Yeah, great to see you, Steve.
STROGATZ: Yeah, wonderful to see you, Janna.
[Music plays]
LEVIN: If you’re enjoying The Joy of Why and you’re not already subscribed, hit the subscribe or follow button wherever you’re listening. You can also leave a review for the show. It helps people find this podcast. Find articles, newsletters, videos and more at quantamagazine.org.
STROGATZ: The Joy of Why is a podcast from Quanta Magazine, an editorially independent publication supported by the Simons Foundation. Funding decisions by the Simons Foundation have no influence on the selection of topics, guests or other editorial decisions in this podcast or in Quanta Magazine.
The Joy of Why is produced by PRX Productions; the production team is Caitlin Faulds, Jade Abdul-Malik, Genevieve Sponsler, and Merritt Jacob. The Executive Producer of PRX Productions is Jocelyn Gonzales. Edwin Ochoa is our project manager.
From Quanta Magazine, Simon Frantz and Samir Patel provided editorial guidance, with support from Samuel Velasco, Kit Sudol, Simone Barr, and Michael Kanyongolo. Samir Patel is Quanta’s Editor-in-Chief.
The episode art is by Chanelle Nibbelink and our logo is by Jaki King and Kristina Armitage. Special thanks to Garth Avery at the Cornell Broadcast Studio.
I’m your host, Steve Strogatz. If you have any questions or comments, please email us at [email protected]. Thanks for listening!
[Music ends]

quanta

文章目录


    扫描二维码,在手机上阅读